Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/21/19 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 11/21/19 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
5 | |
| 11/19/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 11/19/19 | DEF 14A | Definitive proxy statements |
|
30 | |
| 11/14/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
107 |
| 11/14/19 | 8-K | Current report filing |
|
12 | |
| 11/12/19 | 8-K | Current report filing |
|
24 | |
| 11/12/19 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions |
|
24 | |
| 11/12/19 | 8-K | Current report filing |
|
4 | |
| 10/16/19 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions |
|
27 |
